MDLN vs. STE: Medline vs. STERIS Stock Comparison

Company Profile

Medline (MDLN) and STERIS (STE) both belong to the Health Care Equipment & Supplies industry, though MDLN is classified under Health Care Supplies while STE falls under Health Care Equipment.

STERIS (STE) has been public since June 1, 1992, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. STERIS (STE) has a non-negative beta of 0.81.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and STE need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Medline (MDLN) at 4.85% and STERIS (STE) at 11.61% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

STERIS (STE) at 13.41% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

STERIS (STE) at 19.18% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: STERIS (STE) reports revenue growth of 8.73%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Both companies show strong earnings momentum, but Medline (MDLN) at 117.38% is the standout with EPS growth above its industry range; STERIS (STE) at 27.90% also sits in the top quartile.

Growth Metrics

Financial Strength

STERIS (STE) at 2.05 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Both Medline (MDLN) at 0.65 and STERIS (STE) at 0.28 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile STERIS (STE) reports a yield of 1.02%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile STERIS (STE) reports a payout of 30.61%, ranking against industry peers normally.

Dividend Metrics

Valuation

STERIS (STE) at 29.93 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

On P/S ratio, both Medline (MDLN) at 1.70 and STERIS (STE) at 3.97 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Medline (MDLN) at 2.95 and STERIS (STE) at 3.38 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics